Friedrich Grimminger
Overview
Explore the profile of Friedrich Grimminger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
318
Citations
11575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rako Z, Cekay M, Yogeswaran A, Yildiz S, Arndt P, Kremer N, et al.
Ann Am Thorac Soc
. 2025 Mar;
PMID: 40042816
Rationale: Echocardiographic indicators of pulmonary hypertension have been reported to predict decreased survival in lung cancer. Objective: We tested the hypothesis that this may be associated with impaired right ventricular...
2.
Yogeswaran A, Funderich M, Olschewski H, Kovacs G, Kiely D, Lawrie A, et al.
ERJ Open Res
. 2025 Feb;
11(1).
PMID: 40008170
Introduction: The definition of pulmonary hypertension (PH) was recently changed and led to a new subset of PH patients with mildly impaired pulmonary haemodynamics, characterised by a mean pulmonary artery...
3.
Husain-Syed F, Enke U, Lubbecke F, Fassbinder W, Grimminger F, Birk H
Blood Purif
. 2025 Feb;
:1-7.
PMID: 39908004
No abstract available.
4.
Wenderoth T, Feldotto M, Hernandez J, Schaffer J, Leisengang S, Pflieger F, et al.
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337391
Oxylipins and specialized pro-resolving lipid mediators (SPMs) derived from polyunsaturated fatty acids (PUFAs) are mediators that coordinate an active process of inflammation resolution. While these mediators have potential as circulating...
5.
Tello K, Yogeswaran A, Majeed R, Kiely D, Lawrie A, Brittain E, et al.
Chest
. 2024 Aug;
167(1):224-240.
PMID: 39182575
Background: Patients with COPD frequently demonstrate pulmonary hypertension (PH). Severe PH in patients with COPD, identified by pulmonary vascular resistance (PVR) of > 5 Wood units (WU), is closely linked...
6.
Cekay M, Arndt P, Franken J, Wilhelm J, Pullamsetti S, Roller F, et al.
BMJ Open Respir Res
. 2024 Aug;
11(1).
PMID: 39179271
Background: Cancer is one of the leading causes of death worldwide, and cardiopulmonary comorbidities may further adversely affect cancer prognosis. We recently described lung cancer-associated pulmonary hypertension (PH) as a...
7.
Ghofrani H, Gomberg-Maitland M, Zhao L, Grimminger F
Nat Rev Cardiol
. 2024 Aug;
22(2):105-120.
PMID: 39112561
Substantial progress has been made in the management of pulmonary arterial hypertension (PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for PAH are mostly limited...
8.
Yogeswaran A, Grimminger J, Tello K, Becker L, Seeger W, Grimminger F, et al.
Pulm Circ
. 2024 Aug;
14(3):e12397.
PMID: 39105131
The PEGASUS study is the first multicentric and prospective assessment of the safety of air travel flying in pulmonary hypertension (PH) (NCT03051763). Data of air travel from 60 patients with...
9.
Arndt P, Turkowski K, Cekay M, Eul B, Grimminger F, Savai R
Clin Sci (Lond)
. 2024 May;
138(11):617-634.
PMID: 38785410
The tumor microenvironment (TME) plays a central role in the development of cancer. Within this complex milieu, the endothelin (ET) system plays a key role by triggering epithelial-to-mesenchymal transition, causing...
10.
Schlueter B, Quanz K, Baldauf J, Petrovic A, Ruppert C, Guenther A, et al.
Vascul Pharmacol
. 2024 May;
155:107379.
PMID: 38762131
Pulmonary hypertension (PH) is a progressive, severe and to date not curable disease of the pulmonary vasculature. Alterations of the insulin-like growth factor 1 (IGF-1) system are known to play...